Posted by : ZeroRisk Cases Marketing
December 6, 2022: Today, the federal judge overseeing the Zantac class action lawsuit has dismissed every Zantac claim to the MDL. In a lengthy Order, the court ruled that the Plaintiffs failed to meet their scientific burden of proof showing that the NDMA in Zantac increased the risk of developing cancer. This is the worst possible outcome and it could ultimately blow up this litigation. Yes, plaintiffs will appeal to the 11th Circuit, and, yes, we think the trial judge’s ruling is incorrect. But this is a dark day in the Zantac litigation.
December 7, 2022: What is next in the Zantac MDL class action? There will be an appeal to the 11th Circuit Court of Appeals. Will an appeal be successful? We are hopeful but that is hard to project. Cases that have not been filed or Zantac cancer lawsuits in state court in places like Illinois, California, Illinois, and Delaware will continue to move forward, hopefully with judges that have a less restrictive view of what is required to allow a jury to decide these claims.
Recent Posts
- Sudafed Faces Legal Battle: Lawsuit Filed Over Alleged Side Effects
- Research Reveals Connection Between Bacteria In Artificial Tears Eye Drops And Corneal Ulcer, Scarring
- Consumers Seek Justice: Sudafed Faces Class Action Lawsuit For Ineffective Cold Medications
- Camp Lejeune Elective Option Pros and Cons
Categories
- Camp Lejeune
- Client Acquistion
- Client Financing
- Company Business
- Daily Dose of Law
- Digital Display Advertising
- Google Maps Ranking
- Human Trafficking
- Law Firm Info
- Lead Generation
- Litigation Funding
- Mass Tort News
- Mass Tort Signed Cases
- Personal Injury Leads
- Sex Abuse Cases